India Cancer Drug Market Overview, 2031

India’s cancer drug market is under immense pressure to evolve rapidly due to the growing cancer burden and the structural constraints of its healthcare system. With over 1.3 million new cases annually, lung, breast, cervical, colorectal, and oral cancers dominate, and the rising prevalence of liver, prostate, and hematological cancers adds complexity to treatment patterns. The country faces the dual challenge of providing access to cost-effective therapies while integrating innovative treatments that improve survival outcomes. Public hospitals and regional cancer centers, such as AIIMS and Tata Memorial Hospital, often operate under limited budgets and infrastructure, making generics and traditional chemotherapy the backbone of treatment for the majority of patients. In contrast, metropolitan private hospitals are increasingly adopting targeted therapies and immunotherapies, facilitated by modern diagnostic capabilities and molecular profiling. Government programs like the National Cancer Control Program and NPCDCS have emphasized early detection, screening, and improving access to oncology services, particularly in semi-urban and rural regions where delayed diagnosis remains a significant issue. Additionally, policy reforms in drug pricing, accelerated approvals, and inclusion in national reimbursement lists are enabling broader adoption of newer therapies. International collaborations and participation in global clinical trials allow leading Indian hospitals to access innovative treatments early, particularly for advanced or rare cancers. Yet, operational pressures, such as limited infusion units, workforce shortages, and regional disparities, continue to shape adoption patterns. Patients in urban centers often benefit from precision medicine approaches, while rural areas rely heavily on conventional chemotherapy. The evolving landscape reflects a market balancing accessibility with innovation, cost containment with high-quality care, and traditional protocols with emerging advanced therapies, positioning India as both a high-volume and rapidly modernizing oncology market.

According to the research report, "India Cancer Drug Market Outlook, 2031," published by Bonafide Research, the India Cancer Drug market is anticipated to grow at more than 13.04% CAGR from 2026 to 2031. India’s cancer drug supply ecosystem is a mix of domestic production, multinational innovation, and fragmented distribution networks, reflecting the country’s healthcare diversity. Domestic pharmaceutical companies, including Cipla, Sun Pharma, and Dr. Reddy’s, dominate the generic chemotherapy segment, supplying low-cost, high-volume treatments widely used in public hospitals. In contrast, innovative therapies such as immunotherapies, monoclonal antibodies, and targeted drugs are largely supplied by multinational firms like Roche, Novartis, and Pfizer through licensing, joint ventures, and direct subsidiaries. Distribution channels vary significantly, with national wholesalers supplying hospital pharmacies and regional centers, while specialized distributors manage high-cost biologics and temperature-sensitive drugs. Hospitals and oncology centers often rely on integrated logistics services to ensure cold-chain compliance, infusion management, and inventory accuracy. After-sales support, such as clinical training, pharmacovigilance, and patient adherence programs, is increasingly a key factor in vendor selection, especially for high-cost or complex therapies. Government procurement processes, particularly in public hospitals, enforce strict pricing and quality standards, influencing supplier strategies. Urban tertiary hospitals benefit from direct partnerships with manufacturers to facilitate access to the latest therapies, while rural and semi-urban areas rely on distributors and regional hubs. The ecosystem also includes emerging online pharmacy channels for oral therapies, providing home delivery and prescription management. Overall, India’s supply-side network balances affordability and innovation, integrating domestic generics with imported advanced drugs, and emphasizing logistics, patient support, and compliance to serve a geographically and socioeconomically diverse population.

India’s oncology drug market features a spectrum of therapy types ranging from traditional chemotherapy to advanced targeted therapies, immunotherapies, hormonal treatments, and combination regimens. Chemotherapy remains the most widely used treatment, especially in government hospitals and smaller urban centers, where generic formulations are preferred for cost-effectiveness. Chemotherapy is administered for breast, cervical, colorectal, lung, and oral cancers, often combined with radiation therapy or surgery. Targeted therapies have been gradually adopted in urban tertiary hospitals, particularly for breast, lung, and hematological cancers, enabled by increased use of biomarker testing and molecular diagnostics. Monoclonal antibodies, tyrosine kinase inhibitors, and other small molecule inhibitors are slowly replacing conventional chemotherapy in certain indications for eligible patients. Immunotherapy is gaining traction in India’s oncology landscape, primarily in leading private hospitals and specialized cancer centers in metropolitan cities. Immune checkpoint inhibitors and emerging cell-based therapies are being used in melanoma, lung cancer, and specific blood cancers, though access remains limited due to cost. Hormonal therapy continues to be widely used for hormone-sensitive cancers like breast and prostate cancer and is commonly integrated with chemotherapy and targeted therapies in advanced stages. Emerging treatments, including combination regimens, antibody-drug conjugates, and biosimilars, are gradually entering the market, facilitated by regulatory approvals and participation in international clinical trials. Hospitals consider both clinical efficacy and operational feasibility when adopting therapies, balancing high-volume chemotherapy with selective use of innovative drugs. India’s oncology market reflects a dual approach: broad chemotherapy coverage ensures accessibility and affordability, while targeted and immune-based therapies drive growth in urban, high-capacity hospitals with advanced diagnostic infrastructure.

Cancer drug demand in India is shaped by disease prevalence, regional demographics, and access to modern therapies. Breast cancer represents the largest indication, particularly in urban areas, with treatment protocols involving chemotherapy, hormonal therapy, targeted therapy, and immunotherapy based on receptor status. Cervical cancer is a major public health concern, especially in rural regions, where chemotherapy and emerging targeted therapies are used for advanced disease stages. Lung cancer, including both non-small cell and small cell types, accounts for high mortality, with adoption of tyrosine kinase inhibitors, monoclonal antibodies, and immune checkpoint inhibitors in private and tertiary hospitals. Colorectal cancer incidence is increasing in urban populations, treated with chemotherapy, targeted therapies, and combination regimens. Prostate cancer is predominantly managed with hormonal therapy and occasionally targeted therapy in advanced stages. Blood cancers such as leukemia, lymphoma, and multiple myeloma are treated in specialized hospitals with biologics, targeted agents, and immunotherapies. Gastric, liver, kidney, and ovarian cancers form smaller but clinically significant segments, where advanced therapies are increasingly applied in urban centers. Oral, brain, bladder, thyroid, and skin cancers collectively contribute to oncology drug demand, primarily in high-capacity hospitals with access to modern treatments. Indication-based allocation reflects both prevalence and the ability of hospitals to adopt innovative therapies, with public institutions relying on cost-effective chemotherapy and private/tertiary centers leading in targeted and immune-based therapy adoption. This structure ensures coverage for high-burden cancers while enabling gradual penetration of advanced therapies across a diverse patient population.

Cancer drugs in India are delivered primarily via injectable and oral routes, each supporting specific clinical and operational needs. Injectable therapies dominate for chemotherapy, biologics, and immunotherapies, which require infusion monitoring, precise dosing, and hospital administration. Public hospitals and tertiary cancer centers maintain infusion units for intravenous and subcutaneous treatments, particularly for aggressive cancers such as breast, lung, colorectal, and hematologic malignancies. Injectable administration is critical for high-efficacy regimens, combination therapies, and immune-based treatments that require monitoring for adverse events. Oral cancer drugs are increasingly used for targeted therapies and hormonal treatments, enabling patients to receive therapy at home and reducing hospital dependency. Oral therapies, including tyrosine kinase inhibitors and hormonal agents, are particularly suitable for long-term maintenance therapy, but adherence monitoring is essential. Hospitals, pharmacies, and patient support programs provide counseling, follow-up, and digital reminders to ensure compliance. Combining injectable and oral therapies allows clinicians to customize regimens based on cancer type, stage, patient lifestyle, and resource availability. The dual-route strategy aligns with India’s heterogeneous healthcare system, balancing cost-effectiveness in public hospitals with patient-centered convenience in private settings. The approach also enables the integration of modern targeted therapies into outpatient care, expanding access while optimizing resource utilization. Overall, route-of-administration strategies in India ensure that both high-volume chemotherapy and high-value targeted or immune therapies reach patients safely and effectively.



India’s cancer drug distribution system combines hospital-based pharmacies, retail outlets, specialty pharmacies, and emerging online platforms to ensure access across public and private sectors. Hospital pharmacies are the primary distribution channel, particularly for injectable chemotherapy, immunotherapy, and biologic therapies requiring infusion supervision. Public hospitals procure drugs through government tenders, centralized procurement schemes, and state-run supply chains, ensuring affordability for large patient volumes. Tertiary hospitals and private oncology centers maintain in-house pharmacies to manage high-cost targeted and immune therapies, coordinating inventory, dosing schedules, and patient monitoring. Retail pharmacies distribute oral therapies and supportive medications, often providing patient counseling, adherence monitoring, and follow-up support. Large pharmacy chains and specialty outlets facilitate access to high-cost oral targeted drugs, working with distributors for cold-chain management and stock maintenance. Online pharmacies are gradually emerging, particularly in urban centers, to provide home delivery of oral cancer drugs and prescription management. Pharmaceutical distributors and logistics providers are critical for ensuring cold-chain compliance, secure transportation, and regulatory adherence, particularly for monoclonal antibodies, biologics, and immunotherapies. After-sales services, including patient education, training for healthcare professionals, and infusion support, further enhance the reliability of distribution networks. India’s multi-channel system ensures that public hospitals, private clinics, and retail pharmacies collectively provide broad access to cancer drugs while maintaining operational efficiency, regulatory compliance, and patient safety across diverse regions.
Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Other Treatment Types
By Indication
• Breast Cancer
• Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma))
• cervical cancer
• Stomach/ Gastric Cancer
• Others (Liver Cancer ,Kidney Cancer (Renal Cell Carcinoma) , ovarian Cancer, Bladder Cancer, Skin Cancer, Brain tumor, Thyroid Cancer )
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies / Drug Stores
• Online Pharmacies